Carlyle(CG)

Search documents
Carlyle and North Bridge Announce Strategic Partnership to Provide Up to $1 Billion in C-PACE Financing
Prnewswire· 2024-09-16 12:15
NEW YORK, Sept. 16, 2024 /PRNewswire/ -- Global investment firm Carlyle (NASDAQ: CG) today announced a strategic investment into North Bridge ESG LLC ("North Bridge"), a leading provider of real estate finance solutions, and a commitment to provide up to $1 billion to facilitate the origination of commercial property assessed clean energy (C-PACE) loans by North Bridge. This partnership leverages Carlyle's strategic growth, real estate, and asset-backed finance expertise and enables North Bridge to address ...
Carlyle Issues Shares for Debt and Announces Settlement
Newsfile· 2024-09-12 23:00
Vancouver, British Columbia--(Newsfile Corp. - September 12, 2024) - CARLYLE COMMODITIES CORP. (CSE: CCC) (FSE: BJ4) (OTC: CCCFF) ("Carlyle" or the "Company") announces that, further to its news release dated September 5, 2024, it has issued 3,806,920 common shares (each, a "Share") at a deemed price of $0.05 per Share to certain directors (the "Insiders") of the Company and certain consultants of the Company as payment of debt in the aggregate amount of $190,346, to settle certain amounts owed by the Compa ...
Carlyle Group: Great Value Pick Amid Improving PE Landscape (Rating Upgrade)
Seeking Alpha· 2024-09-11 12:46
alexsl We see increasing evidence that deal flows for private equity asset managers are improving as the U.S. economy enters into a new monetary easing cycle. Acording to a recent report published by the Financial Times, four of the largest U.S. private capital groups, including Ares (ARES), Apollo (APO), Blackstone (BX), and KK R (KKR), have deployed a combined US$162bn in Q2 alone. Eamings data compiled by Bloomberg also indicate that seven of the world's largest private equity asset managers collectively ...
Abingworth appoints Robert DeBenedetto as Managing Director – Clinical Co-Development
GlobeNewswire News Room· 2024-09-10 08:00
London, UK and New York, USA, September 10, 2024 - Abingworth, a leading transatlantic life sciences investment firm and part of global investment firm Carlyle (NASDAQ: CG), today announced the appointment of Robert (Bob) DeBenedetto as Managing Director – Clinical Co-Development. Bob brings to Abingworth over 30 years of experience in the life sciences industry and will be working on Clinical Co-Development deals and execution with new and existing Abingworth portfolio companies. He will be based in Abingw ...
Investors are 'dramatically overestimating' an oil glut, Carlyle's Jeff Currie says
CNBC· 2024-09-10 06:14
An oil pump jack is shown in a field on June 27, 2024 in Stanton, Texas. Concerns about a supply glut in the markets are "completely overplayed," Currie said at the annual Asia Pacific Petroleum Conference in Singapore, attributing it to excessive pessimism about Chinese demand amid flat U.S. crude oil production. SINGAPORE — Global markets are severely overplaying an oil supply glut, said Jeff Currie, chief strategy officer of energy pathways at private equity giant Carlyle. The key issue there is, the mar ...
OHA is Administrative Agent & Lead Left Arranger of Private Unitranche Financing Supporting Carlyle's Acquisition of Worldpac
GlobeNewswire News Room· 2024-09-09 20:14
New York, New York, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Oak Hill Advisors ("OHA") served as Administrative Agent and Lead Left Arranger of a private unitranche facility to support Carlyle's acquisition of Worldpac, Inc. ("Worldpac"), a formerly fully owned subsidiary of Advance Auto Parts, Inc. Worldpac is a national distributor of original equipment and quality aftermarket replacement automotive parts, primarily to independent service professionals. OHA provided the entire unitranche financing facility, whi ...
Carlyle Announces Issuance of Shares for Debt
Newsfile· 2024-09-05 22:30
Vancouver, British Columbia--(Newsfile Corp. - September 5, 2024) - CARLYLE COMMODITIES CORP. (CSE: CCC) (FSE: BJ4) (OTC Pink: CCCFF) ("Carlyle" or the "Company") announces that it has agreed to issue an aggregate of 3,806,920 common shares (each, a "Share") at a deemed price of $0.05 per Share to certain directors of the Company (the "Insiders") and certain consultants of the Company as payment of debt in the aggregate amount of $190,346 (the "Debt Settlement"), to settle certain amounts owed by the Compan ...
Acentra Health Awarded a $298 Million Contract Renewal from the Centers for Medicare & Medicaid Services to Continue Improving Care Quality for Medicare Beneficiaries
GlobeNewswire News Room· 2024-09-05 13:53
MCLEAN, Va., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for government healthcare agencies and the priority populations they serve, announced that the Centers for Medicare & Medicaid Services (CMS) has renewed its five-year contract as a Beneficiary and Family Centered Care-Quality Improvement Organization (BFCC-QIO) through April 30, 2029. The renewal of Acentra Health's services to support Medicare ben ...
Acentra Health CEO Todd Stottlemyer Named to Virginia Business Magazine's ‘500 Power List' of Most Influential Leaders
GlobeNewswire News Room· 2024-09-03 13:47
MCLEAN, Va., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for government healthcare agencies and the priority populations they serve, announced today that Virginia Business Magazine has named CEO Todd Stottlemyer to its 2024 Virginia 500 Power List, which recognizes the commonwealth's most powerful and influential leaders in business, government, and education. This is the third year in a row he has been n ...
Spectral Medical Provides August Tigris Trial Update
GlobeNewswire News Room· 2024-09-03 11:30
TORONTO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company's Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion ("PMX") in a randomized controlled trial of adults treated for endotoxemia and septic shock. Tigris Enrollment: Robust enrollment into the second half of 2024, which continues the pa ...